ES2192394T3 - Profarmacos de inhibidores de la bomba de protones. - Google Patents

Profarmacos de inhibidores de la bomba de protones.

Info

Publication number
ES2192394T3
ES2192394T3 ES99942057T ES99942057T ES2192394T3 ES 2192394 T3 ES2192394 T3 ES 2192394T3 ES 99942057 T ES99942057 T ES 99942057T ES 99942057 T ES99942057 T ES 99942057T ES 2192394 T3 ES2192394 T3 ES 2192394T3
Authority
ES
Spain
Prior art keywords
carbons
alkyl
alkoxy
substituted
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99942057T
Other languages
English (en)
Inventor
Michael E Garst
George Sachs
Jai Moo Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Winston Pharmaceuticals LLC
National Aeronautics and Space Administration NASA
US Department of Veterans Affairs
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Winston Pharmaceuticals LLC
National Aeronautics and Space Administration NASA
US Department of Veterans Affairs
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/131,481 external-priority patent/US6093734A/en
Application filed by Winston Pharmaceuticals LLC, National Aeronautics and Space Administration NASA, US Department of Veterans Affairs, University of California Berkeley, University of California San Diego UCSD filed Critical Winston Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2192394T3 publication Critical patent/ES2192394T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Reciprocating Pumps (AREA)
  • Fertilizing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de la fórmula Het1 - X - S(O)- Het2 en donde Het1 se selecciona a partir del grupo que consta de las estructuras mostradas por las fórmulas a continuación **(Fórmula)** X se selecciona a partir del grupo que consta de las estructuras mostradas por las fórmulas a continuación **(Fórmula)** y Het2 se selecciona a partir del grupo consistente en las estructuras mostradas por las fórmulas a continuación **(Fórmula)** en donde N en el resto bencimidazol representa que uno de los carbonos del anillo se puede intercambiar por un átomo de N no sustituido; **(Fórmula)** R1, R2 y R3 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con flúor, alcoxi de 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con flúor, alquiltio de 1 a 10 carbonos, alquiltio de 1 a 10 carbonos sustituido con flúor, alcoxialcoxi de 2 a 10 carbonos, amino, alquilamino y dialquilamino teniendo cada uno de los grupos alquilo en dichos grupos alquilamino y dialquilamino 1 a 10 carbonos, halógeno, fenilo, fenilo sustituido con alquilo, fenilo sustituido con alcoxi, fenilalcoxi, teniendo cada uno de los grupos alquilo en dicho fenilo sustituido con alquilo, fenilo sustituido con alcoxi y fenilalcoxi, 1 a 10 carbonos, piperidino, morfolino o dos de los grupos R1, R2y R3 forman conjuntamente un anillo de 5 o 6 miembros que tienen 0 o 1 heteroátomo seleccionado entre N, S y O; R4 y R5 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo sustituido con flúor de 1 a 10 carbonos, fenilalquilo, naftilalquilo y heteroarilalquilo, teniendo el alquilo en dichos grupos fenilalquilo, naftilalquilo y heteroarilalquilo 1 a 10 carbonos; R6, es hidrógeno, halógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con flúor, alcoxi que tiene 1 a 10 carbonos o alcoxi sustituido con flúor que tiene 1 a 10 carbonos; R6 a R9 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con halógeno, alcoxi de 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con halógeno, alquil carbonilo, alcoxicarbonilo teniendo el grupo alquilo en dicho alquil carbonilo y alcoxicarbonilo 1 a 10 carbonos, oxazolilo, imidazolilo, tiazolilo, pirazolilo o cualquiera de los dos adyacentes a los grupos R6 a R9 puede formar un anillo que puede incluir opcionalmente un heteroátomo seleccionado entre N, O y S; R10 es hidrógeno, alquilo de 1 a 10 carbonos; R11 y R12 se seleccionan independientemente entre hidrógeno, halógeno, alquilo de 1 a 10 carbonos y alquilo de 1 a 10 carbonos sustituido con halógeno; R15 tiene la fórmula siguiente **(Fórmula)** en donde R17 es alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con halógeno, alcoxi que tiene 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con halógeno, alquiltio que tiene 1 a 10 carbonos, alquiltio de 1 a 10 carbonos sustituido con halógeno, alcoxi carbonilo que tiene 1 a 10 carbonos, alcoxi carbonilo que tiene 1 a 10 carbonos sustituido con halógeno, F, Cl, Br, I, NO2, CN, OCOalquilo, NH2, alquilamino y dialquilamino, en donde en dichos grupos OCOalquilo, alquilamino y dialquilamino cada uno de dichos grupos alquilo tiene 1 a 10 carbonos, carbamoílo, carbamoílo sustituido en N, alquilcarbonilo que tiene 1 a 10 carbonos, grupos (alcoxicarbonil)alcoxi en donde cada uno de dichos grupos alcoxi tiene 1 a 10 carbonos, grupos (alcoxicarbonil)alquilo en donde cada uno de dichos grupos alcoxi o alquilo tiene 1 a 10 carbonos, (carbamoil)alcoxi que tiene 1 a 10 carbonos, (N-alquilcarbamoil)alcoxi que tiene 1 a 10 carbonos, (N, N-dialquilcarbamoil)alcoxi que tiene 1 a 10 carbonos, poli((carbamoil sustituido en N o no sustituido)alcoxi) que tiene 1 a 10 carbonos, (carbamoil sustituido en N o no sustituido)alquilo que tiene 1 a 10 carbonos, [N-(heteroaril)carbamoil]alquilo que tiene 1 a 10 carbonos, [N-(heteroaril)carbamoil]alcoxi que tiene 1 a 10 carbonos, [N-(heteroaril sustituido)carbamoil]alcoxi que tiene 1 a 10 carbonos, [N-(aril sustituido)carbamoil]alcoxi que tiene 1 a 10 carbonos, grupo poli(alcoxi) en donde cada uno de dichos grupos alcoxi tiene 1 a 10 carbonos, polialcoxi cíclico, grupo guanidinilo, grupo ureido, grupo poli(dialquilamino - alcoxi), [N - (carbamoilalquil)carbamoil]alcoxi, [N - (carbamoilalquil)carbamoil]alquilo, [N - [[N - (heteroaril)carbamoil]alquil]carbamoil]alcoxi, [N - [[N - (heteroaril sustituido)carbamoil]alquil]carbamoil]alcoxi, [(tri - alquil)amonio]alcoxi, (sulfonato)alquilo, (sulfonato)alcoxi, N - [sulfonato)alquil]amido, maleimido (sustituido), succinimido (sustituido); y R21 es (aril)alquilo, (heteroaril)alquilo, fenilo, naftilo o heteroarilo que tiene 1 a 3 heteroátomos seleccionados independientemente entre N, O y S, estando dichos grupos fenilo, naftilo o heteroarilo, sustituidos o no sustituidos con 1 a 5 grupos R17, o a una sal farmacéuticamente aceptable de dicho compuesto.
ES99942057T 1998-08-10 1999-08-09 Profarmacos de inhibidores de la bomba de protones. Expired - Lifetime ES2192394T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/131,481 US6093734A (en) 1998-08-10 1998-08-10 Prodrugs of proton pump inhibitors
US36438199A 1999-07-29 1999-07-29

Publications (1)

Publication Number Publication Date
ES2192394T3 true ES2192394T3 (es) 2003-10-01

Family

ID=26829517

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99942057T Expired - Lifetime ES2192394T3 (es) 1998-08-10 1999-08-09 Profarmacos de inhibidores de la bomba de protones.

Country Status (27)

Country Link
US (1) US6559167B1 (es)
EP (1) EP1105387B1 (es)
JP (1) JP4346243B2 (es)
KR (1) KR100472126B1 (es)
CN (1) CN100396675C (es)
AT (1) ATE231857T1 (es)
AU (1) AU752292B2 (es)
BG (1) BG64870B1 (es)
BR (1) BR9912937A (es)
CA (1) CA2338311C (es)
DE (1) DE69905171T2 (es)
DK (1) DK1105387T3 (es)
ES (1) ES2192394T3 (es)
FI (1) FI20010248A7 (es)
HR (1) HRP20010106A2 (es)
HU (1) HUP0103464A3 (es)
ID (1) ID28273A (es)
IL (2) IL141083A0 (es)
IS (1) IS5826A (es)
MX (1) MXPA01001464A (es)
NO (1) NO322490B1 (es)
NZ (1) NZ510180A (es)
PL (1) PL346000A1 (es)
TR (1) TR200100431T2 (es)
UA (1) UA67788C2 (es)
WO (1) WO2000009498A1 (es)
YU (1) YU10101A (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020637A1 (en) * 2001-11-19 2005-01-27 Wolfgang-Alexander Simon Agents for the treatment of airway disorders
RU2292342C2 (ru) * 2002-07-19 2007-01-27 Уинстон Фармасьютикалс ЛЛС. Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
JP2006188432A (ja) * 2003-02-25 2006-07-20 Zeria Pharmaceut Co Ltd 四環系スルフェンアミド化合物
JP2007521314A (ja) * 2003-07-15 2007-08-02 アラーガン、インコーポレイテッド プロトンポンプ阻害薬の異性体純粋なプロドラッグを製造するための方法
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
ATE437869T1 (de) * 2004-04-28 2009-08-15 Hetero Drugs Ltd Verfahren zur herstellung von pyridinylmethyl-1h- benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
US7365206B2 (en) * 2004-05-28 2008-04-29 Hetero Drugs Limited Stereoselective synthesis of benzimidazole sulfoxides
WO2006009734A1 (en) * 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
WO2006009736A1 (en) * 2004-06-17 2006-01-26 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
CA2581623A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
CN101048383A (zh) * 2004-11-23 2007-10-03 惠氏公司 促性腺激素释放激素受体拮抗剂
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) * 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) * 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical INJECTION
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
US20100113524A1 (en) * 2006-09-19 2010-05-06 Garst Michael E Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
CN101497622B (zh) * 2008-01-30 2011-04-27 山东轩竹医药科技有限公司 吡啶甲基亚磺酰基咪唑并吡啶衍生物
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
CN104718189B (zh) * 2012-11-19 2017-03-15 江苏豪森药业集团有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
WO2014133059A1 (ja) 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN115667934A (zh) 2020-05-20 2023-01-31 豪夫迈·罗氏有限公司 质谱用试剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
ES2140391T3 (es) * 1990-06-20 2000-03-01 Astra Ab Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5945425A (en) * 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
HK1035368A1 (en) 2001-11-23
BG105191A (bg) 2001-12-29
CN1312806A (zh) 2001-09-12
JP4346243B2 (ja) 2009-10-21
EP1105387B1 (en) 2003-01-29
WO2000009498A1 (en) 2000-02-24
HUP0103464A2 (hu) 2002-02-28
IL141083A0 (en) 2002-02-10
UA67788C2 (uk) 2004-07-15
NO20010693L (no) 2001-03-05
DK1105387T3 (da) 2003-06-23
AU752292B2 (en) 2002-09-12
US6559167B1 (en) 2003-05-06
MXPA01001464A (es) 2002-05-08
BR9912937A (pt) 2001-05-08
DE69905171T2 (de) 2003-11-20
HRP20010106A2 (en) 2002-02-28
NO322490B1 (no) 2006-10-09
HUP0103464A3 (en) 2002-11-28
IL141083A (en) 2006-07-05
ID28273A (id) 2001-05-10
NO20010693D0 (no) 2001-02-09
CA2338311C (en) 2007-01-23
NZ510180A (en) 2002-11-26
FI20010248A7 (fi) 2001-04-09
CA2338311A1 (en) 2000-02-24
EP1105387A1 (en) 2001-06-13
CN100396675C (zh) 2008-06-25
KR20010103566A (ko) 2001-11-23
PL346000A1 (en) 2002-01-14
TR200100431T2 (tr) 2001-06-21
FI20010248L (fi) 2001-02-09
BG64870B1 (bg) 2006-07-31
YU10101A (sh) 2003-10-31
JP2003534232A (ja) 2003-11-18
ATE231857T1 (de) 2003-02-15
AU5551899A (en) 2000-03-06
DE69905171D1 (de) 2003-03-06
IS5826A (is) 2001-01-29
KR100472126B1 (ko) 2005-03-08

Similar Documents

Publication Publication Date Title
FI831604L (fi) Pyridinderivat, deras framstaellning och anvaendning
ES2190264T3 (es) N-(2-aril-propionil)sulfonamidas y preparaciones farmaceuticas que las contienen.
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
ATE316961T1 (de) Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
PT93111A (pt) Processo para a preparacao de compostos heterociclicos contendo pelo menos dois atomos de azoto no anel
DK0624584T3 (da) Piperazinderivater, der er nyttige som calmodulininhibitorer
RU2004119406A (ru) 5-сульфанил-4н-1,2,4-триазольные производные и их применение в качестве лекарственного препарата
AR057244A1 (es) Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes.
EA200001172A1 (ru) Терапевтические диарильные производные
HUP0402026A2 (hu) 5,6-Diaril-pirazin-2-amid-származékok mint CB1 antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BE1002226A5 (fr) Derives de 4h-benzopyranne-1 one-4 et leurs sels, leurs procedes de fabrication et compositions pharmaceutiques les comprenant en tant qu'ingredients actifs.
ES2075849T3 (es) Derivados heterociclicos.
BG100511A (en) Indole derivatives as nmda antagoniosts
RU2002129100A (ru) Гетероциклические производные и лекарственные средства
RU97103983A (ru) Лекарственные композиции и производные триазина
RU2004119963A (ru) Ингибиторы вич интегразы
RU2003130752A (ru) Противозудные средства
CO4810374A1 (es) Nueva utilizacion de compuestos para actividad anti- pruritica
DK270289D0 (da) Oligopeptider med cycliske, prolin-analoge aminosyrer og farmaceutisk acceptable salte deraf samt deres anvendelse
GB1369401A (en) Process for the manufacture of 2-amino-1,4-dihydropyridines and their use as coronary agents
DE68925933D1 (de) Arylalkylamine und -amide mit krampflösender und nervenschützender Wirkung
KR910000133A (ko) 아민
RU2002118708A (ru) Гетероциклические производные и лекарственные средства
AR015140A1 (es) N-(3,4-dihidro-2h-piran-4-il)sulfonamidas, procedimiento para su preparacion, su utilizacion para la preparacion de un medicamento, un preparadofarmaceutico y medicamento
RU2003123119A (ru) Модуляторы натриевых каналов, являющиеся производными 2-пиперидилимидазолов